Experience

Zai Lab Enters License and Collaboration Agreement with Blueprint Medicines

November 10, 2021

Cooley advised Zai Lab on its exclusive collaboration and license agreement with Blueprint Medicines for the development and commercialization of BLU-945 and BLU-701 for the treatment of patients with epidermal growth factor receptor (EGFR) -driven non-small cell lung cancer (NSCLC) in Greater China, including mainland China, Hong Kong, Macau and Taiwan. 
 
Under the terms of the agreement, Blueprint Medicines will receive an upfront cash payment of $25 million and will be eligible to receive up to $590 million in potential development, regulatory and sales-based milestone payments, and tiered royalties on a product-by-product basis ranging from the low-teens to mid-teens on annual net sales of BLU-945 and BLU-701 in Greater China, subject to adjustment in specified circumstances. In addition, Zai Lab will be responsible for all the development costs for BLU-945 and BLU-701 occurring in Greater China and will receive the rights to develop and exclusively commercialize BLU-945 and BLU-701 in the region.
 
Lawyers Lila Hope and Jennifer Raab led the Cooley team advising Zai Lab.

 

Related contacts

Lila Hope
Partner, Palo Alto
Jennifer Raab
Partner, Palo Alto

Related Practices & Industries

I-Mab Enters Global Strategic Partnership With AbbVie for Cancer Treatment

September 10, 2020

Cooley advised I-Mab on its global collaboration agreement with AbbVie for the development and commercialization of lemzoparlimab, one of I-Mab’s leading drug candidates, for the treatment of multiple cancers. Lawyers Lila Hope and Jennifer Raab led the Cooley team advising I-Mab on the agreement. 

Read more

Related contacts

Lila Hope
Partner, Palo Alto
Jennifer Raab
Partner, Palo Alto
Amanda Pacheco
Associate, Palo Alto
Jeffrey J. Tolin
Partner, New York
Rachel Thorn
Partner, New York
Andrew Epstein
Special Counsel, Seattle

Related Practices & Industries

CardioKinetix Completes $50 Million Financing

December 19, 2014

Cooley advised CardioKinetix on its $50 million financing led by Edwards Lifesciences. CardioKinetix also entered into an agreement with Edwards Lifesciences that provides the company with the right to acquire CardioKinetix based on future regulatory milestones.

CardioKinetix is a medical device company pioneering a catheter-based treatment for heart failure.

Related contacts

Mark Weeks
Partner, Palo Alto
Barbara Borden
Partner, San Diego
Mark Windfeld-Hansen
Senior Counsel, Palo Alto
Lila Hope
Partner, Palo Alto
Sepideh Mousakhani
Partner, Palo Alto

Related Practices & Industries

Adamas Pharmaceuticals Initial Public Offering

April 30, 2014

San Francisco – Cooley advised Adamas Pharmaceuticals on its initial public offering. Adamas, a specialty pharmaceutical company driven to improve the lives of those affected by chronic disorders of the central nervous system, now trades on the Nasdaq Global Stock Market under the symbol "ADMS."

Thus far in 2014, Cooley has advised on 43 completed public offerings, including 22 completed IPOs.

Related contacts

Kenneth Guernsey
Senior Counsel , San Francisco
Danielle Naftulin
Partner, Palo Alto
Mark Windfeld-Hansen
Senior Counsel, Palo Alto
Natasha Leskovsek
Of Counsel, Washington, DC
Michael Tuscan
Partner, Washington, DC
Fraser Brown
Partner, Washington, DC
Lila Hope
Partner, Palo Alto
Bin Wang
Special Counsel, Palo Alto
Jennifer Raab
Partner, Palo Alto

Related Practices & Industries

Ascendis Pharma closes $124 million IPO

February 13, 2015

Cooley advised the underwriters on Ascendis Pharma's $124.2 million initial public offering. Ascendis Pharma is a clinical-stage biopharmaceutical company applying its TransCon technology to develop a pipeline of therapies to address significant unmet medical needs. The company now trades on the Nasdaq Global Market under the symbol "ASND."

Merrill Lynch, Pierce, Fenner & Smith and Leerink Partners acted as the joint book-running managers, and Wells Fargo Securities acted as co-manager for the offering.

Related contacts

Div Gupta
Partner, New York
Drew Williamson
Partner, San Francisco
Charlie Kim
Partner, San Diego
Natasha Leskovsek
Of Counsel, Washington, DC
Bill Christiansen
Partner, Seattle
Lila Hope
Partner, Palo Alto
Jonie Ing Kondracki
Partner, San Francisco
Kristin VanderPas
Partner, San Francisco
Phil Mitchell
Partner, New York
Jennifer Raab
Partner, Palo Alto

Related Practices & Industries

View more

Rankings & accolades

Chambers USA: Life Sciences: Corporate/Commercial – California (2020 – 2023)

The Legal 500: Healthcare: Life Sciences

Duke Law Alumni Awards: Outstanding Volunteer Service Award (2022)

Stanford Associates: Stanford Volunteer Award (2019)

Memberships & affiliations

American Bar Association

Duke Law Board of Visitors, member (2022 – present)

Stanford Medicine Alumni Association, past president (2019 – 2021)

Duke Law Alumni Association, past president (2021 – 2022)

Stanford Medicine Alumni Association, past board member

Duke Law Alumni Association, past board member

Lila has tremendous experience in licensing and complex agreements. She has a pragmatic approach and really understands the business needs of her clients.

Chambers USA: Life Sciences: Corporate/Commercial – California (2022)